TP53 and cancer: Among these patients, 64% possess one distinct TP53 mutation and 36% possess two distinct TP53 mutations; however, the two-hit hypothesis postulates that both TP53 alleles must be lost to elicit a pathogenic effect, which is the case for >90% of human cancers.